VBI

VBI Vaccines Reports Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 16, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, Sale, Net, GAAP, MLE, Walmart, Pharmacy, Green Book, Government, Hepatitis B vaccine, Green, Prison, Research and development, Partnership, Control arm, GBM, Vaccine, Administration, Disease, Exercise, Patient, Carmustine, CAD, VBI, Hepatitis B, Messenger, Bank statement, Israeli new shekel, Internationalized domain name, Growth, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
  • Revenues, net: Revenues, net for the full year 2023 were $8.7 million as compared to $1.1 million for the same period in 2022.
  • Cost of Revenues: Cost of revenues was $12.5 million for the full year 2023 as compared to $11.3 million in 2022.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Pharmaceutical, Oncology, Health, FDA, Infectious Diseases, Clinical Trials, Other Health, File, Sale, Disease, Prospectus, 3rd Floor, Vaccine, Security (finance), VBI

The gross proceeds to VBI from this offering were approximately $2 million, before deducting the placement agent’s fees and other offering expenses.

Key Points: 
  • The gross proceeds to VBI from this offering were approximately $2 million, before deducting the placement agent’s fees and other offering expenses.
  • VBI intends to use the net proceeds from this offering for working capital and general corporate purposes.
  • The offering of the securities in the registered direct offering was made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement.
  • A prospectus supplement and accompanying prospectus relating to the registered direct offering have been filed with the SEC.

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Tuesday, April 9, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, 3rd Floor, Disease, Vaccine, Sale, Security (finance), Prospectus, File, VBI, Regulation D

In a concurrent private placement, VBI will issue unregistered warrants to purchase up to 2,272,728 common shares.

Key Points: 
  • In a concurrent private placement, VBI will issue unregistered warrants to purchase up to 2,272,728 common shares.
  • The gross proceeds to VBI from this offering are expected to be approximately $2 million, before deducting the placement agent’s fees and other offering expenses.
  • The offering of the securities in the registered direct offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement.
  • A prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

Retrieved on: 
Wednesday, April 3, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Toxicity, Combination therapy, SOC, Survival, Disease, Patient, GBM, Vaccine, Neoplasm, Decompression (diving), Safety, VBI, Pharmaceutical industry

The multi-center, randomized, controlled, open-label study has been designed to evaluate overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy in rGBM patients.

Key Points: 
  • The multi-center, randomized, controlled, open-label study has been designed to evaluate overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy in rGBM patients.
  • Dr. Anderson commented: “In recurrent GBM, tumors typically double or triple in size within six weeks, with no effective treatments available to improve survival.
  • Early indications from this ongoing study suggest tumor growth behavior in-line with expectations for both the standard-of-care arm and the VBI-1901 arm, based on positive data seen from the Phase 1/2a study.
  • As of March 22, 2024, 17 patients have been randomized 1:1 to either the active, VBI-1901 treatment arm, or to the control, standard-of-care treatment arm (SoC).

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Strategic Innovation Fund, Disease, Partnership, Vaccine, RNA, Messenger, MLE, National Research Council, Government, CAD, VBI

In preclinical studies, VBI’s MLE candidates generated strong B-cell and T-cell signals compared to those seen with other mRNA vaccines tested.

Key Points: 
  • In preclinical studies, VBI’s MLE candidates generated strong B-cell and T-cell signals compared to those seen with other mRNA vaccines tested.
  • The technology platform also offers potential for streamlined manufacturing timelines, similar to other mRNA vaccines.
  • “We are grateful for the continued support of our long-term partners in the Canadian government, and are pleased to extend our work together to investigate our novel MLE platform, which we think has the potential to revolutionize particulate vaccines,” said Jeff Baxter, President and CEO of VBI.
  • Consistent with the strategic intent of the original agreement, development will primarily focus on platform development and will also include a pan-coronavirus MLE candidate to contribute toward future epidemic and pandemic preparedness.

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024
Fabry disease, RMB, PD, Drug development, Strong, Ohio State University, RNA, Insight Partners, Pharmacology, American College, Radiopharmaceutical, VBI, Willebrand, RTW, Pattern hair loss, GMP, Stroke, Good manufacturing practice, Therapy, Skin, GCS, Atopic dermatitis, Safety, Pharmacokinetics, Von Willebrand factor, Investment, AstraZeneca, Innovation, Groundbreaking, Patient, ARCH Venture Partners, Pharmaceutical industry

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

Retrieved on: 
Wednesday, February 14, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Burn, GBM, Vaccine, Patient, Rehovot, Disease, VBI, Public

Additionally, subject to certain approvals, VBI and Brii Bio will work together to transfer the manufacturing technologies of VBI-2601 to a site designated by Brii Bio.

Key Points: 
  • Additionally, subject to certain approvals, VBI and Brii Bio will work together to transfer the manufacturing technologies of VBI-2601 to a site designated by Brii Bio.
  • VBI received $2.5 million of consideration upon signing of definitive documents and is expected to receive up to an additional $30.5 million of consideration, subject to achievement of certain activities, with a target completion date of June 30, 2024.
  • Jeff Baxter, President and CEO of VBI, stated: “We believe that this transaction improves the financial stability of VBI and balances the potential value creation within our development and commercial portfolio with a streamlined and focused resource deployment.
  • Upon successful completion of all transactions, we anticipate that we will have reduced the long-term burn of the company, and reduced our debt overhang by about 70%.

RTC Aerospace Acquires Vanderhorst Brothers Industries

Retrieved on: 
Tuesday, January 16, 2024
Defense, Aerospace, Manufacturing, Other Manufacturing, Other Defense, Contracts, RTC, Acquisition, VBI, Original equipment manufacturer

RTC Aerospace LLC (“RTC”), a leading manufacturer of high-precision, difficult-to-machine components for commercial and military aircraft and varied aerospace and defense applications, announced today that it has acquired Vanderhorst Brothers Industries (“VBI”).

Key Points: 
  • RTC Aerospace LLC (“RTC”), a leading manufacturer of high-precision, difficult-to-machine components for commercial and military aircraft and varied aerospace and defense applications, announced today that it has acquired Vanderhorst Brothers Industries (“VBI”).
  • Based in Simi Valley, CA, and founded in 1973, VBI has been led by Brian, Juno and son Bob O’Rell for over 20 years, becoming a preeminent manufacturer of precision components to the aerospace, defense, and space industries.
  • “We are deeply impressed with the RTC team and are excited for the combined future of the two firms,” said Brian O’Rell.
  • We are excited to have provided our support to the RTC team during the acquisition and look forward to additional opportunities for strategic acquisitions in the coming years.”

Patria Investments Signs Agreement to Acquire Credit Suisse's Real Estate Business in Brazil

Retrieved on: 
Wednesday, December 6, 2023
Credit Suisse, Real estate, Acquisition, AUM, REIT, VBI, Growth, UBS, IPO, Finance, Real

GRAND CAYMAN, Cayman Islands, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Patria Investments Limited (“Patria”) (NASDAQ: PAX), a global alternative asset manager and market leader in Latin America, announces the signing of an agreement for the acquisition of Credit Suisse's Real Estate business in Brazil (“CSHG Real Estate”), for total cash consideration of up to R$ 650 million (~US$ 130 million).

Key Points: 
  • GRAND CAYMAN, Cayman Islands, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Patria Investments Limited (“Patria”) (NASDAQ: PAX), a global alternative asset manager and market leader in Latin America, announces the signing of an agreement for the acquisition of Credit Suisse's Real Estate business in Brazil (“CSHG Real Estate”), for total cash consideration of up to R$ 650 million (~US$ 130 million).
  • The funds are listed on the Brazilian stock exchange, and together would add up to R$ 12 billion (~US$ 2.4 billion) in assets under management to Patria’s Real Estate platform.
  • Patria has taken significant steps in recent years to scale its Real Estate platform in Latin America, now with a strong presence in Brazil, Colombia and Chile, and more than US$ 3 billion in real estate assets under management as of November 2023.
  • Positioning CSHG Real Estate alongside VBI, Patria is expected to become the largest independent REIT manager in Brazil, reinforcing the attractive opportunities for asset management consolidation in this fragmented market.

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

Retrieved on: 
Monday, November 20, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Neurology, Research, Infectious Diseases, Science, Clinical Trials, Education, Toxicity, Progression-free survival, Disease, GBM, Vaccination, Patient, Tumor microenvironment, VBI, Vaccine, Survival, Society, SNO, HIV disease progression rates, Traffic barrier, Pharmaceutical industry

New proof-of-mechanism data demonstrated that vaccination with VBI-1901 was associated with T-cell activation capable of trafficking across the blood-brain barrier to the tumor microenvironment, an area which is known to be highly immunosuppressive and difficult to infiltrate.

Key Points: 
  • New proof-of-mechanism data demonstrated that vaccination with VBI-1901 was associated with T-cell activation capable of trafficking across the blood-brain barrier to the tumor microenvironment, an area which is known to be highly immunosuppressive and difficult to infiltrate.
  • Additionally, higher levels of C4G after vaccination with VBI-1901 have been associated with longer progression-free survival.
  • “We are very pleased to share these significant mechanistic findings at SNO,” said David E. Anderson, Ph.D., VBI’s Chief Scientific Officer.
  • “The GBM tumor microenvironment is notoriously immunosuppressive and difficult to penetrate, which is why most treatment needs to be administered intratumorally, and why there are currently so few effective treatment options for patients.